The initiation of the Merah Putih vaccine was carried out before the merger of Eijkman into BRIN.
REPUBLIKA.CO.ID, JAKARTA — President Director (Director) of PT Biofarma Honesti Basyir said, the development of red and white vaccine keep going. Although the Eijkman Institute for Biology and Molecular (LBM) has now been merged into the National Research and Innovation Agency (BRIN).
“There is no problem, we have initiated this (Red and White vaccine) from the start. We have also coordinated with BRIN. no issue,” said Honesti at Nusantara I Building, Parliament Complex, Jakarta, Wednesday (12/1).
Currently, the Red and White vaccine is in the optimization stage of the existing three prototype sirvacin. He said that the optimization process is getting better and clinical trials will soon be carried out.
“It has to be tested industrially, is the scale good or not? I see. So how many times have we optimized it, at the present stage we will immediately enter preclinical testing on animals,” Honesti said.
Head of the National Research and Innovation Agency (BRIN) Laksana Tri Handoko also said that the development of the Red and White vaccine is still ongoing. Even though LBM Eijkman has been merged into the institution.
“Red and white vaccines are still running, if those with recombinant protein are now looking for yield higher,” said Handoko.
He explained, the Eijkman team at BRIN are focused on improving yield or productivity of Red and White vaccine seeds. Enhancement yield Vaccine seeds are carried out in the laboratory for optimization of various parameters.
“This is looking for yield higher, so that it won’t be too expensive when it’s finished. So let it go first,” said Handoko.